Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 1
1972 1
1975 1
1976 1
1978 2
1979 1
1980 1
1981 1
1982 1
1983 1
1984 3
1985 3
1986 1
1987 1
1988 2
1989 3
1990 2
1992 3
1993 1
1994 1
1995 2
1996 2
1997 2
1998 4
1999 1
2006 1
2007 1
2008 1
2009 4
2010 4
2011 4
2012 2
2013 4
2014 4
2015 10
2016 3
2017 3
2018 8
2019 4
2020 9
2021 3
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.
Pichler AC, Carrié N, Cuisinier M, Ghazali S, Voisin A, Axisa PP, Tosolini M, Mazzotti C, Golec DP, Maheo S, do Souto L, Ekren R, Blanquart E, Lemaitre L, Feliu V, Joubert MV, Cannons JL, Guillerey C, Avet-Loiseau H, Watts TH, Salomon BL, Joffre O, Grinberg-Bleyer Y, Schwartzberg PL, Lucca LE, Martinet L. Pichler AC, et al. Among authors: martinet l. Immunity. 2023 Jul 11;56(7):1631-1648.e10. doi: 10.1016/j.immuni.2023.06.007. Epub 2023 Jun 30. Immunity. 2023. PMID: 37392737 Free PMC article.
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.
Braun M, Aguilera AR, Sundarrajan A, Corvino D, Stannard K, Krumeich S, Das I, Lima LG, Meza Guzman LG, Li K, Li R, Salim N, Jorge MV, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Effern M, Quine B, Koufariotis LT, Casey M, Nakamura K, Seo EY, Hölzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes BGM, Wilmott JS, Long GV, Scolyer RA, Batstone MD, Landsberg J, Dietrich D, Pop OT, Flatz L, Dougall WC, Veillette A, Nicholson SE, Möller A, Johnston RJ, Martinet L, Smyth MJ, Bald T. Braun M, et al. Among authors: martinet l. Immunity. 2020 Oct 13;53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010. Immunity. 2020. PMID: 33053330 Free article.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S, Diallo BK, El-Murr N, Carrié N, Tang A, Fournier A, Bonnevaux H, Nicolazzi C, Cuisinier M, Arnould I, Sidhu SS, Corre J, Avet-Loiseau H, Teillaud JL, van de Velde H, Wiederschain D, Chiron M, Martinet L, Virone-Oddos A. Kassem S, et al. Among authors: martinet l. Blood. 2022 Feb 24;139(8):1160-1176. doi: 10.1182/blood.2021012448. Blood. 2022. PMID: 35201323 Free article.
Making Drawings Speak Through Mathematical Metrics.
Sueur C, Martinet L, Beltzung B, Pelé M. Sueur C, et al. Among authors: martinet l. Hum Nat. 2022 Dec;33(4):400-424. doi: 10.1007/s12110-022-09436-w. Epub 2022 Dec 14. Hum Nat. 2022. PMID: 36515859
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.
Schavgoulidze A, Perrot A, Cazaubiel T, Leleu X, Montes L, Jacquet C, Belhadj K, Brechignac S, Frenzel L, Chalopin T, Rey P, Schiano de Collela JM, Dib M, Caillot D, Macro M, Fontan J, Buisson L, Pavageau L, Roussel M, Manier S, Mohty M, Martinet L, Avet-Loiseau H, Corre J. Schavgoulidze A, et al. Among authors: martinet l. Blood Cancer J. 2023 Oct 26;13(1):160. doi: 10.1038/s41408-023-00933-4. Blood Cancer J. 2023. PMID: 37880285 Free PMC article. No abstract available.
DNAM-1: would the real natural killer cell please stand up!
Huntington ND, Martinet L, Smyth MJ. Huntington ND, et al. Among authors: martinet l. Oncotarget. 2015 Oct 6;6(30):28537-8. doi: 10.18632/oncotarget.5952. Oncotarget. 2015. PMID: 26471195 Free PMC article. No abstract available.
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.
Weulersse M, Asrir A, Pichler AC, Lemaitre L, Braun M, Carrié N, Joubert MV, Le Moine M, Do Souto L, Gaud G, Das I, Brauns E, Scarlata CM, Morandi E, Sundarrajan A, Cuisinier M, Buisson L, Maheo S, Kassem S, Agesta A, Pérès M, Verhoeyen E, Martinez A, Mazieres J, Dupré L, Gossye T, Pancaldi V, Guillerey C, Ayyoub M, Dejean AS, Saoudi A, Goriely S, Avet-Loiseau H, Bald T, Smyth MJ, Martinet L. Weulersse M, et al. Among authors: martinet l. Immunity. 2020 Oct 13;53(4):824-839.e10. doi: 10.1016/j.immuni.2020.09.006. Immunity. 2020. PMID: 33053331 Free article.
109 results